🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

16+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 16 of 16 recruiting trials for “epidermolysis-bullosa-simplex”

Phase 2RecruitingNCT06594393 ↗

A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

🏥 Xinnate AB📍 6 sites📅 Started Jan 2026View details ↗
Phase 1, PHASE2RecruitingNCT07193134 ↗

GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

👨‍⚕️ Lucie Germain, PhD, CHU de Québec-Université Laval📍 1 site📅 Started Jan 2026View details ↗
Phase 2RecruitingNCT07027345 ↗

A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

🏥 BioMendics, LLC📍 2 sites📅 Started Sep 2025View details ↗
Phase 1, PHASE2RecruitingNCT06834035 ↗

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

👨‍⚕️ Matt P Marinkovich, MD, Associate Professor of Dermatology📍 1 site📅 Started Aug 2025View details ↗
Phase 3RecruitingNCT07016750 ↗

A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa

🏥 Krystal Biotech, Inc.📍 5 sites📅 Started Jun 2025View details ↗
Phase 3RecruitingNCT06917690 ↗

A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa

🏥 Chiesi Farmaceutici S.p.A.📍 6 sites📅 Started Apr 2025View details ↗
RecruitingNCT06423573 ↗

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

🏥 Amryt Pharma📍 5 sites📅 Started Dec 2024View details ↗
Phase 1, PHASE2RecruitingNCT04173650 ↗

MSC EVs in Dystrophic Epidermolysis Bullosa

👨‍⚕️ David T Woodley, MD, University of Southern California Dept of Dermatology📍 3 sites📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06509984 ↗

A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized

🏥 Centre Hospitalier Universitaire de Nice📍 4 sites📅 Started Aug 2024View details ↗
RecruitingNCT06563414 ↗

A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)

🏥 Krystal Biotech, Inc.📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06177353 ↗

Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro

👨‍⚕️ Reem Al-Daccak, Dr, Institut National de la Santé Et de la Recherche Médicale, France📍 2 sites📅 Started Apr 2024View details ↗
Phase 2, PHASE3RecruitingNCT06073132 ↗

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

🏥 TWi Biotechnology, Inc.📍 36 sites📅 Started Apr 2024View details ↗
Phase 1, PHASE2RecruitingNCT07230223 ↗

Effect of Ev.FV on Wound Healing in Dystrophic Epidermolysis Bullosa

👨‍⚕️ Masoud Soleimani, Prof, Shahid Beheshti University of Medical Sciences📍 1 site📅 Started Jan 2024View details ↗
Phase 2RecruitingNCT05157958 ↗

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

🏥 Anterogen Co., Ltd.📍 1 site📅 Started May 2023View details ↗
RecruitingNCT04917887 ↗

Long-Term Follow-up Protocol

🏥 Krystal Biotech, Inc.📍 3 sites📅 Started May 2021View details ↗
RecruitingNCT01019148 ↗

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

👨‍⚕️ Jean Tang, MD, PhD, Stanford University📍 1 site📅 Started Nov 2009View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →